Aeterna Zentaris Appoints James Clavijo as Chief Financial Officer
March 05 2018 - 4:05PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the
appointment of James Clavijo as Chief Financial Officer effective
March 5, 2018. Mr. Clavijo joins Aeterna Zentaris from Tri-Source
Pharma, where he most recently served as Chief Financial Officer.
Tri-Source is a pharmaceutical company focused on procuring
pharmaceutical products facing supply issues and supplying
pharmaceutical products to veterinary markets.
“We are pleased to welcome James Clavijo to our
leadership team. He brings tremendous financial acumen acquired in
the pharmaceutical, healthcare and manufacturing sectors,” said
Michael V. Ward, Chief Executive Officer of Aeterna Zentaris. “We
believe Mr. Clavijo will be a great asset to our business at this
pivotal time in our lifecycle.”
Prior to serving as Chief Financial Officer of
Tri-Source Pharma, Mr. Clavijo also served for seven years as
founder of Capital View Partners, a consulting firm providing Chief
Financial Officer services, and for five years as the Chief
Accounting Officer at Soligenix, a public biopharmaceutical
company.
“I am looking forward to joining Aeterna
Zentaris and am eager to work with our leadership team to continue
building upon its value creation by expanding the out-licensing of
Macrilen™ (macimorelin),” said James Clavijo.
Mr. Clavijo received a bachelor’s degree in
Chemistry from the University of Florida, a bachelor’s degree in
Accounting from the University of Nebraska, and a master’s degree
in Accounting from Florida International University.
About Aeterna ZentarisAeterna
Zentaris Inc. is a specialty biopharmaceutical company focused on
developing and commercializing, principally through out-licensing
arrangements, Macrilen™ (macimorelin), an orally available ghrelin
agonist, to be used in the diagnosis of patients with adult growth
hormone deficiency (AGHD). On January 17, 2018 Aeterna Zentaris
announced that that it had, through a wholly-owned subsidiary,
entered into a license and assignment agreement with a wholly-owned
subsidiary of Strongbridge Biopharma plc to carry out development,
manufacturing, registration and commercialization of Macrilen™
(macimorelin) in the United States and Canada. On December 20, 2017
the Company announced that the U.S. Food and Drug Administration
(FDA) granted marketing approval for Macrilen™ (macimorelin). On
November 27, 2017 Aeterna Zentaris announced that the Marketing
Authorization Application (MAA) for the use of Macrilen™
(macimorelin) for the evaluation of AGHD was accepted by the
European Medicines Agency (EMA) for regulatory review. For more
information, visit www.aezsinc.com.
For more information, please contact:Aeterna Zentaris
Inc.Michael V. WardChief Executive Officer,
843.900.3201IR@AEZSinc.com
Reilly ConnectSusan J. ReillyPresident,
312.600.6780susan.reilly@reillyconnect.com
Forward-Looking Statements
This press release contains forward-looking
statements made pursuant to the safe-harbor provisions of the U.S.
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws, which reflect our current expectations regarding
future events. Forward-looking statements may include, but are not
limited to statements preceded by, followed by, or that include the
words “will” “expects,” “believes,” “intends,” “would,” “could,”
“may,” “anticipates,” and similar terms that relate to future
events, performance, or our results. Forward-looking statements
involve known risks and uncertainties, many of which are discussed
under the caption “Key Information - Risk Factors” in our most
recent Annual Report on Form 20-F filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission
(“SEC”) and under the caption
“Risk Factors and Uncertainties” in our management’s discussion and
analysis for the third quarter of 2017. Such risks and
uncertainties include, among others, our now heavy dependence on
the success of Macrilen™ (macimorelin) and related out-licensing
arrangements and the continued availability of funds and resources
to successfully launch the product, the ability of Aeterna Zentaris
to enter into out-licensing, development, manufacturing and
marketing and distribution agreements with other pharmaceutical
companies and keep such agreements in effect, reliance on third
parties for the manufacturing and commercialization of our product
candidates, potential disputes with third parties, leading to
delays in or termination of the manufacturing, development,
out-licensing or commercialization of our product candidates, or
resulting in significant litigation or arbitration, and, more
generally, uncertainties related to the regulatory process, the
ability of Aeterna Zentaris to efficiently commercialize or
out-license Macrilen™ (macimorelin), the degree of market
acceptance of Macrilen™ (macimorelin), our ability to obtain
necessary approvals from the relevant regulatory authorities to
enable us to use the desired brand names for our products, the
impact of securities class action litigation, the litigation
involving two former officers of Aeterna Zentaris, or other
litigation, on our cash flow, results of operations and financial
position; any evaluation of potential strategic alternatives to
maximize potential future growth and stakeholder value may not
result in any such alternative being pursued, and even if pursued,
may not result in the anticipated benefits, our ability to take
advantage of business opportunities in the pharmaceutical industry,
our ability to protect our intellectual property, the potential of
liability arising from shareholder lawsuits and general changes in
economic conditions. Investors should consult the quarterly and
annual filings of Aeterna Zentaris with the applicable Canadian
securities regulators and the SEC for additional information on
risks and uncertainties. Given these uncertainties and risk
factors, readers are cautioned not to place undue reliance on these
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce any revisions to any of
the forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or applicable law.
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024